Axsome Therapeutics, Inc.NASDAQ: AXSM

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

· Issued by Axsome Therapeutics, Inc.

On 6ix: 6ix.com/news/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-the-accord-phase-3

Watch Axsome Therapeutics' latest callAxsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call
Axsome Therapeutics' next earnings callAxsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call · Nov 2, 2026 at 8:00 AM ESTRegister

AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint)

AXS-05 statistically significantly prevented relapse of Alzheimer’s disease agitation versus placebo (p=0.018, key secondary endpoint)

Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score, starting at Week 1 with open-label AXS-05 (p

Axsome Therapeutics, Inc. on 6ix

Story so far

Earlier from Axsome Therapeutics

Later from Axsome Therapeutics

All Axsome Therapeutics news releases